All the data previously described suggest that, even if the RAS/RAF/MEK/ERK pathway plays a central role as potential target in HCC patients, its inhibition could not be sufficient to arrest HCC cells development. The gene discussed is MAP2K7; the disease is hepatocellular carcinoma.